{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023887","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.498915+00:00","generated_at":"2026-06-22T01:52:55.832731+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Terns Pharma Q3 net loss $16.8M; cash $187M; pipeline on track for 2023 trials","bullets":["Net loss of $16.8M for Q3 2022 ($0.44 per share), compared to $11.8M ($0.47) in Q3 2021.","Cash, cash equivalents and marketable securities totaled $187.3M at Sept 30, 2022, providing runway into 2025.","R&D expenses rose to $12.2M (Q3 2022) from $7.2M (Q3 2021); G&A expenses were $5.1M vs $4.7M.","Plan to initiate U.S. Phase 1 trial for TERN-701 (allosteric BCR-ABL) in CML in H2 2023; top-line DUET data for TERN-501 expected H2 2023.","IND-enabling activities for TERN-601 (oral GLP-1R) on track; first-in-human obesity trial planned in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023887","json":"https://secwatch.observer/filing/0000950170-22-023887.json","markdown":"https://secwatch.observer/filing/0000950170-22-023887.md","text":"https://secwatch.observer/filing/0000950170-22-023887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022023887/0000950170-22-023887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022023887/tern-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:52:55.832731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a064be65187c4da6fd459401196649d9ed46897d","claim":"Terns Pharmaceuticals, Inc. reported financial results for three and nine months ended September 30, 2022.","evidence_excerpt":"On November 9, 2022, Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017022023887/0000950170-22-023887-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}